Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

abrdn plc lifted its position in Scholar Rock by 28.2% during the third quarter. abrdn plc now owns 748,489 shares of the company’s stock valued at $5,995,000 after buying an additional 164,715 ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

SC upholds Dalit scholars’ right to compensation for loss of research data Uke and Das, both members of Scheduled Caste communities and PhD holders from the Jawaharlal Nehru University ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock is asking the U.S. Food and Drug Administration (FDA) to approve apitegromab, its experimental add-on therapy designed to boost motor function in people with spinal muscular atrophy (SMA) ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and ...

Scholar Rock has done well to advance its anti-myostatin ... but also to see if this drug is ultimately approved to treat this specific neuromuscular patient population. What I wanted to note ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...